» Articles » PMID: 22110944

Dysfunctional Neurotransmitter Systems in Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions on These Systems

Overview
Journal Pain Res Treat
Date 2011 Nov 24
PMID 22110944
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Fibromyalgia is considered a stress-related disorder, and hypo- as well as hyperactive stress systems (sympathetic nervous system and hypothalamic-pituitary-adrenal axis) have been found. Some observations raise doubts on the view that alterations in these stress systems are solely responsible for fibromyalgia symptoms. Cumulative evidence points at dysfunctional transmitter systems that may underlie the major symptoms of the condition. In addition, all transmitter systems found to be altered in fibromyalgia influence the body's stress systems. Since both transmitter and stress systems change during chronic stress, it is conceivable that both systems change in parallel, interact, and contribute to the phenotype of fibromyalgia. As we outline in this paper, subgroups of patients might exhibit varying degrees and types of transmitter dysfunction, explaining differences in symptomatoloy and contributing to the heterogeneity of fibromyalgia. The finding that not all fibromyalgia patients respond to the same medications, targeting dysfunctional transmitter systems, further supports this hypothesis.

Citing Articles

Neuroinflammatory and Immunological Aspects of Fibromyalgia.

Findeisen K, Guymer E, Littlejohn G Brain Sci. 2025; 15(2).

PMID: 40002538 PMC: 11852494. DOI: 10.3390/brainsci15020206.


Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review.

Malik A, Brown Z, Ryder A, Balayan V, Jameson L, Vu P Psychopharmacol Bull. 2025; 55(2):24-40.

PMID: 39935669 PMC: 11809501.


A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.

Garcia-Dominguez M Biomedicines. 2025; 13(1).

PMID: 39857749 PMC: 11762748. DOI: 10.3390/biomedicines13010165.


Metformin and fibromyalgia pathophysiology: current insights and promising future therapeutic strategies.

AboTaleb H, Alghamdi B Mol Biol Rep. 2024; 52(1):60.

PMID: 39692938 DOI: 10.1007/s11033-024-10159-7.


The Effectiveness of the Low-Glycemic and Insulinemic (LOGI) Regimen in Maintaining the Benefits of the VLCKD in Fibromyalgia Patients.

Castaldo G, Marino C, DElia M, Grimaldi M, Napolitano E, DUrsi A Nutrients. 2024; 16(23).

PMID: 39683556 PMC: 11643857. DOI: 10.3390/nu16234161.


References
1.
Giesecke T, Williams D, Harris R, Cupps T, Tian X, Tian T . Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003; 48(10):2916-22. DOI: 10.1002/art.11272. View

2.
Ebner K, Muigg P, Singewald G, Singewald N . Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci. 2008; 1144:61-73. DOI: 10.1196/annals.1418.018. View

3.
Clarke R, Bali I, Issac M, Dundee J, Sheridan B . Plasma cortisol and blood sugar following minor surgery under intravenous anaesthetics. Anaesthesia. 1974; 29(5):545-50. DOI: 10.1111/j.1365-2044.1974.tb00717.x. View

4.
Fayed N, Garcia-Campayo J, Magallon R, Andres-Bergareche H, Luciano J, Andres E . Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther. 2010; 12(4):R134. PMC: 2945024. DOI: 10.1186/ar3072. View

5.
Graven-Nielsen T, Kendall S, Henriksson K, Bengtsson M, Sorensen J, Johnson A . Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000; 85(3):483-491. DOI: 10.1016/S0304-3959(99)00308-5. View